AI assistant
IMMUPHARMA PLC Remuneration Information 2020
7703_def-14a_2020-11-26_033d1219-6aa7-46a4-8906-f566d17a10f4.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 5422G
Immupharma PLC
26 November 2020
| RNS / eCorporate | 26 November 2020 |
ImmuPharma PLC
("ImmuPharma" or the "Company")
Grant of Share Options & PDMR dealing
ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 9,625,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to Directors, employees and consultants representing 3.8% of ImmuPharma's Ordinary Shares and total voting rights (the "Options"). ImmuPharma currently has 250,221,297 Ordinary Shares in issue.
Upon the recommendation of the Company's remuneration committee, the Company has granted the Options pursuant to the Company's Share Option Plan which was adopted on 30 March 2017 (the "2017 Plan").
The exercise price for the Options is 20p being a 54% premium to the closing middle market share price of 13p on 25 November 2020. The Options will vest after three years and are exercisable between three and ten years from the date of grant.
The amount of Options granted to the Directors are summarised in the following table:
| Director | Options Granted |
| Dimitri Dimitriou | 1,500,000 |
| Dr Robert Zimmer | 1,875,000* |
| Tim McCarthy | 1,500,000 |
| Dr Franco di Muzio | 300,000 |
| Dr Stephane Mery | 300,000 |
*Includes 375,000 Options granted to Elizabeth Zimmer, Robert Zimmer's wife who is also an employee of the Company
Following the grant of Options, the Directors will have the following interests in share options in the Company:
| Director | Number of options | Exercise Price | Expiry Date |
| Dimitri Dimitriou | 1,000,000 1,500,000 1,500,000 |
50.25p 98.62p 20.00p |
30.03.2027 24.11.2027 26.11.2030 |
| Dr Robert Zimmer | 50,000* 100,000* 1,250,000* 1,875,000* 1,875,000* |
90.75p 43.88p 50.25p 98.62p 20.00p |
24.11.2021 02.06.2026 30.03.2027 24.11.2027 26.11.2030 |
| Tim McCarthy | 500,000 1,000,000 1,500,000 1,500,000 |
43.88p 56.75p 98.62p 20.00p |
02.06.2026 12.07.2027 24.11.2027 26.11.2030 |
| Dr Franco di Muzio | 100,000 200,000 300,000 300,000 |
43.88p 56.75p 98.62p 20.00p |
02.06.2026 12.07.2027 24.11.2027 26.11.2030 |
| Dr Stephane Mery | 100,000 200,000 300,000 300,000 |
43.88p 56.75p 98.62p 20.00p |
02.06.2026 12.07.2027 24.11.2027 26.11.2030 |
*Includes Options granted to Elizabeth Zimmer, Robert Zimmer's wife who is also an employee of the Company
The Directors currently have the following interests in Ordinary Shares:
| Director | Number of Ordinary Shares | % of issued share capital at 25 November 2020 |
| Dimitri Dimitriou | 3,567,430 | 1.45% |
| Dr Robert Zimmer | 27,344,514* | 11.10% |
| Tim McCarthy | 38,462 | 0.01% |
| Dr Franco di Muzio | 99,412 | 0.04% |
| Dr Stephane Mery | 21,490 | 0.01% |
*includes 22,000,000 shares held by Luca & Associates AG, an entity connected with Dr Zimmer, and of which he is President and a shareholder.
Other grants of Options to Persons Discharging Managerial Responsibilities ("PDMR")
1,500,000 Options have been granted to Tim Franklin, Chief Operating Officer of the Company. Following the grant of these Options, Tim Franklin will hold Options over 1,500,000 Ordinary Shares in the Company. Similarly, 375,000 Options have been granted to Ewa Flynn, Financial Controller of the Company. Following the grant of these Options, Ewa Flynn will hold Options over 375,000 Ordinary Shares in the Company. Neither Dr Franklin nor Ewa Flynn currently hold any interests in Ordinary Shares in the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dimitri Dimitriou | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | ImmuPharma PLC | |
| b) | LEI | 213800VZKGHXC7VUS895 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 10p each ISIN: GB0033711010 |
|
| b) | Nature of the transaction | Grant of share options over Ordinary Shares | |
| c) | Price(s) and volume(s) | Price | Volume |
| Exercise price: 20p per Ordinary Share | 1,500,000 | ||
| d) | Aggregated information - Aggregated volume - Price |
N/A | |
| e) | Date of the transaction | 25 November 2020 | |
| f) | Place of the transaction | Off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dr Robert Zimmer | |
| 2 | Reason for the notification | ||
| a) | Position/status | President & Chief Scientific Officer | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | ImmuPharma PLC | |
| b) | LEI | 213800VZKGHXC7VUS895 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 10p each ISIN: GB0033711010 |
|
| b) | Nature of the transaction | Grant of share options over Ordinary Shares | |
| c) | Price(s) and volume(s) | Price | Volume |
| Exercise price: 20p per Ordinary Share | 1,875,000 (includes 375,000 to Elizabeth Zimmer) |
||
| d) | Aggregated information - Aggregated volume - Price |
N/A | |
| e) | Date of the transaction | 25 November 2020 | |
| f) | Place of the transaction | Off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Tim McCarthy | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Chairman | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | ImmuPharma PLC | |
| b) | LEI | 213800VZKGHXC7VUS895 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 10p each ISIN: GB0033711010 |
|
| b) | Nature of the transaction | Grant of share options over Ordinary Shares | |
| c) | Price(s) and volume(s) | Price | Volume |
| Exercise price: 20p per Ordinary Share | 1,500,000 | ||
| d) | Aggregated information - Aggregated volume - Price |
N/A | |
| e) | Date of the transaction | 25 November 2020 | |
| f) | Place of the transaction | Off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dr Franco Di Muzio | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | ImmuPharma PLC | |
| b) | LEI | 213800VZKGHXC7VUS895 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 10p each ISIN: GB0033711010 |
|
| b) | Nature of the transaction | Grant of share options over Ordinary Shares | |
| c) | Price(s) and volume(s) | Price | Volume |
| Exercise price: 20p per Ordinary Share | 300,000 | ||
| d) | Aggregated information - Aggregated volume - Price |
N/A | |
| e) | Date of the transaction | 25 November 2020 | |
| f) | Place of the transaction | Off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dr Stéphane Méry | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | ImmuPharma PLC | |
| b) | LEI | 213800VZKGHXC7VUS895 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 10p each ISIN: GB0033711010 |
|
| b) | Nature of the transaction | Grant of share options over Ordinary Shares | |
| c) | Price(s) and volume(s) | Price | Volume |
| Exercise price: 20p per Ordinary Share | 300,000 | ||
| d) | Aggregated information - Aggregated volume - Price |
N/A | |
| e) | Date of the transaction | 25 November 2020 | |
| f) | Place of the transaction | Off market |
PDMR Options
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dr Tim Franklin | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Operating Officer | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | ImmuPharma PLC | |
| b) | LEI | 213800VZKGHXC7VUS895 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 10p each ISIN: GB0033711010 |
|
| b) | Nature of the transaction | Grant of share options over Ordinary Shares | |
| c) | Price(s) and volume(s) | Price | Volume |
| Exercise price: 20p per Ordinary Share | 1,500,000 | ||
| d) | Aggregated information - Aggregated volume - Price |
N/A | |
| e) | Date of the transaction | 25 November 2020 | |
| f) | Place of the transaction | Off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Ewa Flynn | |
| 2 | Reason for the notification | ||
| a) | Position/status | Financial Controller | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | ImmuPharma PLC | |
| b) | LEI | 213800VZKGHXC7VUS895 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 10p each ISIN: GB0033711010 |
|
| b) | Nature of the transaction | Grant of share options over Ordinary Shares | |
| c) | Price(s) and volume(s) | Price | Volume |
| Exercise price: 20p per Ordinary Share | 375,000 | ||
| d) | Aggregated information - Aggregated volume - Price |
N/A | |
| e) | Date of the transaction | 25 November 2020 | |
| f) | Place of the transaction | Off market |
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
| ImmuPharma PLC (www.immupharma.com) Tim McCarthy, Chairman |
+ 44 (0) 207 152 4080 |
| Dimitri Dimitriou, Chief Executive Officer | |
| Lisa Baderoon, Head of Investor Relations | + 44 (0) 7721 413496 |
| SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge John Howes Bob Pountney SI Capital (Joint Broker) Nick Emerson |
+44 (0) 203 368 3550 +44 (0) 203 815 8880 +44 (0) 1483 413500 |
| 4Reliance (Euronext Growth Listing Sponsor) Jean-Charles Snoy Degroof Petercam (Liquidity Provider) Erik De Clippel Backstage Communication Olivier Duquaine Gunther De Backer |
+32 (0) 2 747 02 60 +32 (0) 2 287 95 34 +32 (0) 477 504 784 +32 (0) 475 903 909 |
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE). Lupus is an autoimmune disease which if left untreated can be fatal. Preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US.
For additional information about ImmuPharma please visit www.immupharma.com.
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHUVOWRRAUAUAA